Gene therapy using SOD1 protects striatal neurons from experimental stroke
Alexis S Davis1, Heng Zhao, Guo Hua Sun
1Department of Pediatrics, Stanford University School of Medicine, 300 Pasteur Drive R200, Stanford, CA 94305-5237, United States.
Neuroscience Letters
|November 18, 2006
Summary
Gene therapy using copper/zinc superoxide dismutase (SOD1) enhanced neuronal survival after stroke in animal models. This antioxidant approach shows promise for treating cerebral ischemia and preventing neuronal death.
Area of Science:
- Neuroscience
- Genetics
- Biomedical Engineering
Background:
- Reactive oxygen species (ROS) are implicated in neuronal death after cerebral ischemia.
- Copper/zinc superoxide dismutase (SOD1) has demonstrated neuroprotective effects in prior studies using transgenic models.
Purpose of the Study:
- To investigate the efficacy of SOD1 gene therapy in non-transgenic animals for increasing neuronal survival following cerebral ischemia.
- To evaluate the impact of SOD1 overexpression via gene therapy on stroke outcomes.
Main Methods:
- Utilized a neurotropic herpes simplex virus-1 (HSV-1) vector engineered to carry the SOD1 gene.
- Administered the SOD1-expressing vector via injection into the striatum.
- Delivered the vector at different time points: before transient focal cerebral ischemia and 2 hours after ischemia.
Main Results:
- Striatal neuron survival was significantly improved at 2 days post-ischemia.
- A 52% increase in neuron survival was observed when the vector was delivered 12-15 hours prior to ischemia.
- A 53% increase in neuron survival was achieved when vector delivery was delayed until 2 hours post-ischemia.
Conclusions:
- SOD1 gene therapy effectively enhances neuronal survival in non-transgenic models of cerebral ischemia.
- Antioxidant strategies, particularly gene therapy, represent a potential therapeutic avenue for stroke treatment.
- HSV-1 vector delivery of SOD1 shows promise for mitigating ischemic brain injury.
